Chief Business & Strategy Officer, Catapult Medicines Descovery
Mark Samuels is responsible for business development, strategy, communications, and research consortia. He was previously the founding MD of the National Institute for Health Research Office for Clinical Research Infrastructure (NOCRI) and a founder member of the NIHRStrategy Board. The NIHR is responsible for clinical research in the NHS across England, with an annual budget of over £1bn.
Mark established the NOCRI office in Whitehall, working in close collaboration with the Department of Health. He worked with 10 Downing Street to contribute to the Prime Minister’s Strategy for UK Life Sciences. He frequently represented the NIHR in the media. Before the NIHR, he worked in industry as an executive at Roche Diagnostics. Representing the UK diagnostics industry, he co-chaired the Evaluation Pathway programme with Sir Andrew Dillon, which established a way for NICE to evaluate medical devices and diagnostics.
Mark was educated at Queen Mary University of London and Oxford’s Saïd Business School. He also holds a Policy Fellowship at Cambridge University